Neuland Laboratories Ltd
Neuland Laboratories Ltd Share Price Today: Live Updates & Key Insights
Get insights on Neuland Laboratories Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Neuland Laboratories Ltd Share Price Chart
NEULANDLAB at 10 Jul 2026 05:21 PM Pharmaceuticals
19506.00 -36.00(-0.18%)
Lowest Today 19353.00
Highest Today 19730.00
Today's Open 19701.00
Prev. Close 19542.00
52 Week High 20089.00
52 Week Low 10400.15
Neuland Laboratories Ltd Fundamentals
Traded Volume: 24,863
Market Cap(Cr): 25,025.98
Avg Traded Price 19521.86
1 Year return 62.98%
Upper Circuit 19,730
Lower Circuit 19,353
P/E TTM 69.00
P/B Ratio 13.449
Traded Value(Cr) 4849.78
EPS TTM 283.711
Book value/Share 1453.020
Dividend Yield 1Y 0.06%
Neuland Laboratories Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Neuland Laboratories Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Neuland Laboratories Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +2.73%
1M +13.49%
3M +32.49%
1Y +62.98%
YTD +29.76%
Neuland Laboratories Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Neuland Laboratories Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 97154.00
Day Before Yesterday 42475.00
1W Avg 62154.40
1M Avg 53723.71
3M Avg 58809.30
Neuland Laboratories Ltd Technical Details
Neuland Laboratories Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 18938
Support 2 18335
Support 3 17759
Pivot Point : 19514
Resistance 1 20117
Resistance 2 20693
Resistance 3 21296
Neuland Laboratories Ltd Corporate Actions
Neuland Laboratories Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Neuland Laboratories Ltd’s capital allocation strategies.
All
Ex-Date 24-Jul-2026 Type D Description 34.00/share@340.00% Record Date 24-Jul-2026 Ratio 340.00
Ex-Date 18-Jul-2025 Type D Description 12.00/share@120.00% Record Date 18-Jul-2025 Ratio 120.00
Ex-Date 12-Jul-2024 Type D Description 14.00/share@140.00% Record Date - Ratio 140.00
Ex-Date 11-Jul-2023 Type D Description 10.00/share@100.00% Record Date - Ratio 100.00
Ex-Date 14-Jul-2022 Type D Description 5.00/share@50.00% Record Date 15-Jul-2022 Ratio 50.00
Ex-Date 29-Jun-2021 Type D Description 3.00/share@30.00% Record Date - Ratio 30.00
Ex-Date 10-Nov-2020 Type D Description 2.00/share@20.00% Record Date 11-Nov-2020 Ratio 20.00
Ex-Date 18-Feb-2020 Type D Description 2.00/share@20.00% Record Date 20-Feb-2020 Ratio 20.00
Ex-Date 27-Jun-2019 Type D Description 1.20/share@12.00% Record Date - Ratio 12.00
Ex-Date 04-Aug-2016 Type D Description 2.00/share@20.00% Record Date - Ratio 20.00
Ex-Date 06-Aug-2015 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00
Ex-Date 13-Aug-2014 Type R Description /share@4:25% Record Date 14-Aug-2014 Ratio 4:25
Ex-Date 16-Jun-2014 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00
Ex-Date 16-Jun-2014 Type D Description 1.50/share@15.00% Record Date - Ratio 15.00
Ex-Date 24-Jul-2013 Type D Description 1.20/share@12.00% Record Date - Ratio 12.00
Ex-Date 21-Mar-2012 Type R Description /share@5:12% Record Date 23-Mar-2012 Ratio 5:12
Ex-Date 13-Jul-2009 Type D Description 3.50/share@35.00% Record Date - Ratio 35.00
Ex-Date 17-Jul-2008 Type D Description 2.50/share@25.00% Record Date - Ratio 25.00
Ex-Date 11-Jul-2007 Type D Description 2.50/share@25.00% Record Date - Ratio 25.00
Dividends
Announcement Date 24-Jul-2026 Ex Dividend Date 24-Jul-2026 Dividend(%) 340
Announcement Date 18-Jul-2025 Ex Dividend Date 18-Jul-2025 Dividend(%) 120
Announcement Date 12-Jul-2024 Ex Dividend Date 12-Jul-2024 Dividend(%) 140
Announcement Date 11-Jul-2023 Ex Dividend Date 11-Jul-2023 Dividend(%) 100
Announcement Date 14-Jul-2022 Ex Dividend Date 14-Jul-2022 Dividend(%) 50
Announcement Date 29-Jun-2021 Ex Dividend Date 29-Jun-2021 Dividend(%) 30
Announcement Date 10-Nov-2020 Ex Dividend Date 10-Nov-2020 Dividend(%) 20
Announcement Date 18-Feb-2020 Ex Dividend Date 18-Feb-2020 Dividend(%) 20
Announcement Date 27-Jun-2019 Ex Dividend Date 27-Jun-2019 Dividend(%) 12
Announcement Date 04-Aug-2016 Ex Dividend Date 04-Aug-2016 Dividend(%) 20
Announcement Date 06-Aug-2015 Ex Dividend Date 06-Aug-2015 Dividend(%) 15
Announcement Date 16-Jun-2014 Ex Dividend Date 16-Jun-2014 Dividend(%) 15
Announcement Date 16-Jun-2014 Ex Dividend Date 16-Jun-2014 Dividend(%) 15
Announcement Date 24-Jul-2013 Ex Dividend Date 24-Jul-2013 Dividend(%) 12
Announcement Date 13-Jul-2009 Ex Dividend Date 13-Jul-2009 Dividend(%) 35
Announcement Date 17-Jul-2008 Ex Dividend Date 17-Jul-2008 Dividend(%) 25
Announcement Date 11-Jul-2007 Ex Dividend Date 11-Jul-2007 Dividend(%) 25
Bonus
No Bonus has been declared by NEULANDLAB
Splits
No Split has been declared by NEULANDLAB
Others
Ex-Rights Date 13-Aug-2014 Premium(Rs.) 194.00 Ratio 4:25
Ex-Rights Date 21-Mar-2012 Premium(Rs.) 35.00 Ratio 5:12
Neuland Laboratories Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Neuland Laboratories Ltd with leading peers in the pharmaceuticals & biotechnology sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Neuland Laboratories Ltd's relative performance and valuation against major competitors.
Stock Name Wockhardt Ltd ₹1810.70 (-1.12%) M. Cap (Cr) 294.22 1 Yr Return (%) +5.46% P/E (TTM) 138.13 PB Ratio 5.96
Stock Name Acutaas Chemicals Ltd ₹3400.80 (-1.68%) M. Cap (Cr) 278.43 1 Yr Return (%) +201.86% P/E (TTM) 78.15 PB Ratio 16.84
Stock Name Sai Life Sciences Ltd ₹1265.00 (+2.48%) M. Cap (Cr) 268.54 1 Yr Return (%) +61.90% P/E (TTM) 76.97 PB Ratio 10.81
Stock Name Neuland Laboratories Ltd ₹19506.00 (-0.18%) M. Cap (Cr) 250.26 1 Yr Return (%) +62.98% P/E (TTM) 68.75 PB Ratio 13.35
Stock Name Rubicon Research Ltd ₹1431.40 (+1.72%) M. Cap (Cr) 236.73 1 Yr Return (%) NaN% P/E (TTM) 95.94 PB Ratio 18.37
Stock Name Piramal Pharma Ltd ₹177.16 (+3.01%) M. Cap (Cr) 235.86 1 Yr Return (%) -12.06% P/E (TTM) -72.37 PB Ratio 2.89
Stock Name Granules India Ltd ₹889.85 (+0.88%) M. Cap (Cr) 220.50 1 Yr Return (%) +85.56% P/E (TTM) 37.06 PB Ratio 4.34
Neuland Laboratories Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Neuland Laboratories Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2026 347.58 Mar 2025 317.49 Mar 2024 260.06 Mar 2023 238.53 Mar 2022 58.60
PARTICULARS Investing Activities Mar 2026 -423.74 Mar 2025 -298.14 Mar 2024 -149.67 Mar 2023 -61.50 Mar 2022 -93.72
PARTICULARS Financing Activities Mar 2026 20.98 Mar 2025 24.96 Mar 2024 -69.28 Mar 2023 -135.80 Mar 2022 37.72
PARTICULARS Net Cash Flow Mar 2026 -55.07 Mar 2025 44.31 Mar 2024 41.11 Mar 2023 41.24 Mar 2022 2.60
Neuland Laboratories Ltd Shareholding Pattern
This shows the ownership breakdown of Neuland Laboratories Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 32.63%
Public 31.08%
Other Institutions 4.49%
FII 20.46%
Mutual Funds 11.35%
About Neuland Laboratories Ltd
Incorporated on January 7, 1984, Neuland Laboratories Limited (NLL) is promoted by Davuluri Sucheth Rao. The Company is engaged in manufacturing and selling of bulk drugs such as Salbutamol Sulphate, Terbutaline Sulphate, Labetalol Hydrochloride and Ciprofloxacin. Neuland Drugs & Pharmaceuticals Pvt. Ltd., a company set up by the same promoters to manufacture bulk drugs was merged with the Company effective from April, 1992. NLL manufactures bulk drugs.The Company came out with its initial public offering in Apr.'94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr.NLL's products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate.During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form.Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI.The Company commenced commercial production of Ramipril, a cardiovascular drug for export to certain markets in 2002.The Company commenced commercial production of Citalopram Hydrobromide, an anti depressant, Pirbuterol Acetate, a bronchodilator, Levofloxacin, an anti bacterial, Levetiracetam, an anti convulsant in 2003.A subsidiary company of Neuland Laboratories Ltd was incorporated on January 4, 2007 in the State of Delaware, USA with its principal office in Orange County, California. During the year 2008-2009, Neuland Laboratories K.K., Japan was incorporated as a subsidiary of Company.During 2012-13, Company undertook a major reorganisation of businesses aimed at de-leveraging on one hand and on other hand narrowing the focus on core activities: APIs, Intermediates and Contract Manufacturing. Consequently, the Company divested its R&D activities by selling its Land and Building and some identified intellectual properties to Neuland Pharma Research Private Limited and its Peptides Research activities along with identified intellectual properties to Neuland Health Sciences Private Limited. It entered into a Joint Business Arrangement with API Corporation, Japan, a part of Mitsubishi Chemical, for manufacturing and sale of APIs and Intermediates.During 2013-14, the Company enhanced its product bouquet by launching 5 more products. It also enhanced its development portfolio to 22 molecules/ APIs created for launch between 2013 and 2016. It opened new office in New Jersey, provide them with quick support and coordinate in various business activities.In 2018, the Board of Directors of the Company approved the Scheme of Amalgamation of Neuland Health Sciences Private Limited and Neuland Pharma Research Private Limited with the Company, on April 1, 2016, the Appointed Date of Scheme. Pursuant to the Scheme of Amalgamation, 45,90,608 equity shares held by Neuland Health Sciences Private Limited in the Company were cancelled and the Company allotted 68,61,243 equity shares to the shareholders of Neuland Health Sciences Private Limited and Neuland Pharma Research Private Limited on April 13, 2018 and further 1,675,000 equity shares were issued and allotted under Qualified Institutional Placement (QIP). The Company acquired Advanced Intermediates and API facility Unit 3, with a capacity of about 197 kiloliters at Gaddapotharam Village, in Sanga Reddy District, in 2018-19. The Unit III was commercialised with 320 kL reaction volume in FY 2023.
Executive Chairman
D R Rao
Registered office 11 Th Floor Phoenix IVY Buildi, Plot No 573A-III Road No 82, Hyderabad, Telangana, 500035
FAX :91-40-30211600
Background
Incorporation Year 1984
Face Value ₹10.00
Market Lot 1
FAQs on Neuland Laboratories Ltd
How to buy Neuland Laboratories Ltd shares?
To buy Neuland Laboratories Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the market cap of Neuland Laboratories Ltd?
The company has a market capitalization of ₹25,025.98.
What is the PE & PB ratio of Neuland Laboratories Ltd?
PE is 69 and PB is 13.449.
What is the Neuland Laboratories Ltd dividend for 2025–26?
For the 2025–26 financial year, Neuland Laboratories Ltd declared a final dividend of 0.06% per share.